Characterization of AAV vectors: A review of analytical techniques and critical quality attributes.

AAV CQAs analytical methodologies capsid identity characterization critical quality attributes gene therapy genetic identity viral vector

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
12 Sep 2024
Historique:
medline: 5 9 2024
pubmed: 5 9 2024
entrez: 5 9 2024
Statut: epublish

Résumé

Standardized evaluation of adeno-associated virus (AAV) vector products for biotherapeutic application is essential to ensure the safety and efficacy of gene therapies. This includes analyzing the critical quality attributes of the product. However, many of the current analytical techniques used to assess these attributes have limitations, including low throughput, large sample requirements, poorly understood measurement variability, and lack of comparability between methods. To address these challenges, it is essential to establish higher-order reference methods that can be used for comparability measurements, optimization of current assays, and development of reference materials. Highly precise methods are necessary for measuring the empty/partial/full capsid ratios and the titer of AAV vectors. Additionally, it is important to develop methods for the measurement of less-established critical quality attributes, including post-translational modifications, capsid stoichiometry, and methylation profiles. By doing so, we can gain a better understanding of the influence of these attributes on the quality of the product. Moreover, quantification of impurities, such as host-cell proteins and DNA contaminants, is crucial for obtaining regulatory approval. The development and application of refined methodologies will be essential to thoroughly characterize AAV vectors by informing process development and facilitating the generation of reference materials for assay validation and calibration.

Identifiants

pubmed: 39234444
doi: 10.1016/j.omtm.2024.101309
pii: S2329-0501(24)00125-6
pmc: PMC11372808
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

101309

Informations de copyright

Crown Copyright © 2024 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Auteurs

Theodoros Kontogiannis (T)

School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, Kent CT2 7NJ, UK.
National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK.

Julian Braybrook (J)

National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK.

Christopher McElroy (C)

National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK.

Carole Foy (C)

National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK.

Alexandra S Whale (AS)

National Measurement Laboratory at LGC, Teddington, Middlesex TW11 0LY, UK.

Milena Quaglia (M)

Reading Scientific Services Ltd, Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading Berkshire RG6 6LA, UK.

C Mark Smales (CM)

School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury, Kent CT2 7NJ, UK.
National Institute for Bioprocessing Research and Training, Blackrock, Co, Foster Avenue, A94 X099 Mount Merrion, Dublin, Ireland.

Classifications MeSH